BioSpace News Archive

The latest market analysis report published by Reports and Data, titled ‘Global Purified Human Proteins Market – Forecast to 2027,’ thoroughly examines the Purified Human Proteins industry to provide essential data & information for the targeted readers.

The global Cardiac Rhythm Management Devices market size is expected to be worth around US$ 39.9 billion by 2030, according to a new report study.

According to Report, the global Cell Therapy market size is expected to be worth around US$ 45 billion by 2030. The global Cell Therapy market size was valued at US$ 15 billion in 2021 and is anticipated to grow at a CAGR of 14.9% during forecast period 2022 to 2030.

According to a new report, the global Clot Management Devices market size is expected to be worth around US$ 2.15 billion by 2030. The global Clot Management Devices market size was valued at US$ 1.5 billion in 2020 and is anticipated to grow at a CAGR of 14.6% during forecast period 2021 to 2030.

Arch Therapeutics, Inc. (OTCQB: ARTH) (“ Arch ” or the “ Company ”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that it completed a private placement through the issuance of senior secured convertible notes .

Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on developing advanced therapies for autoimmune and inflammatory diseases, today announced that a patient has completed the course of investigational nomacopan treatment in the open-label, multi-center Phase III Part A clinical trial in pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA).

Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, today announced that it has appointed Dr. Ellen Strahlman and Dr. Ram Palanki as new and independent members of its Board of Directors.

Origin Therapeutics Holdings Inc. is pleased to announce that it has added Clairvoyant Therapeutics (“ Clairvoyant ”) to its portfolio.

Tempest Therapeutics, Inc. today announced that Tom Dubensky, Ph.D., will participate in a panel titled “Developing Therapies for the Next Immuno-Oncology Targets” at the 2022 William Blair Biotech Focus Conference on Tuesday, July 12, 2022 at 4:10 p.m. ET.

CorDx, a global leader in the development, manufacturing, and distribution of diagnostics and medical devices, recently unveiled a new facility here with innovations designed to make medical diagnostic products more accessible and affordable for healthcare professionals and end users alike.